Dr Zahra Rattray

Strathclyde Chancellor's Fellow

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Chancellor's Fellow and Lecturer

My field of expertise lies in the characterization of biologics and nanomedicine formulation attributes and in vivo performance using traditional and novel analytical approaches. 

Areas of interest are summarized as follows;

  • Understanding environmental and physicochemical determinants of solution-phase formulation stability.
  • Determining key critical quality attributes in particle design to inform optimal in vivo performance.
  • Evaluation of nanomedicine interaction with biological media, and the mechanism of cellular uptake in two- and three-dimensional cellular models.
  • Applying novel imaging modalities for evaluating drug and nanoparticle biodistribution, and impact on tumor response.
  • The interplay between the tumour microenvironment and nanomedicine in vivo performance with a view to developing biorelevant in vitro tests.

I am passionate about improving access to education, achievement and realizing potential for young budding scientists and am open to local STEM and healthcare-related widening participation initiatives. I am co-director (Pharmacy) with Dr Margaret Cunningham (Biomedical Sciences) for outreach in the Strathclyde Institute of Pharmacy & Biomedical Sciences.

Publications

Evaluation of temporal aggregation processes using spatial intensity distribution analysis
Rattray Zahra, Zindy Egor, Buzza Karen M, Pluen Alain
Protein Self-Assembly (2019) (2019)
https://doi.org/10.1007/978-1-4939-9678-0_11
A DNA-damaging lupus autoantibody synergizes with PARP inhibitors against DNA repair-deficient tumor cells
Rattray Zahra, Patel Jaymin M, Noble Phillip W, Dubljevic Valentina, Greenwood Deanne L, Campbell James A, Hansen James E
Cancer Research Vol 78, pp. 2773 (2018)
https://doi.org/10.1158/1538-7445.AM2018-2773
Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications
Rattray Zahra, Dubljevic Valentina, Rattray Nicholas, Greenwood Deanne L, Johnson Caroline H, Campbell James A, Hansen James E
Biochemical and Biophysical Research Communications Vol 496, pp. 858-864 (2018)
https://doi.org/10.1016/j.bbrc.2018.01.139
Compositions and methods for inhibition of nuclear-penetrating antibodies
Rattray Zahra, Hansen James
(2018)
Compositions and methods for enhancing nuclear translocation
Rattray Zahra, Hansen James E
(2018)
Metabolomics guided pathway analysis reveals link between cancer metastasis, cholesterol sulfate, and phospholipids
Johnson Caroline H, Santidrian Antonio F, LeBoeuf Sarah E, Kurzy Michael E, Rattray Nicholas, Rattray Zahra, Warth Benedikt, Ritland Melissa, Hoang Linh T, Loriot Celine, Higa Jason, Hansen James E, Felding Brunhilde H, Siuzdak Gary
Cancer and Metabolism Vol 5 (2017)
https://doi.org/10.1186/s40170-017-0171-2

more publications

Professional activities

Nanotechnology: a blessing or a curse for developing nations?
Interviewee
1/8/2019
Science @ Strathclyde - SIPBS: Virtual Drug Discovery Workshop
Advisor
11/6/2019
Senior Phase Induction Day @ Strathclyde: SIPBS Virtual Drug Discovery Workshop
Advisor
6/6/2019
Health Week @ Garrowhill Primary School: Diabetes and Asthma Workshops
Advisor
31/5/2019
Day of Science @ Strathclyde - SIPBS: Cat Allergy Simulation and STEM activity stands
Advisor
9/5/2019
Integrative Technologies in Precision Medicine
Contributor
25/3/2019

more professional activities

Projects

Doctoral Training Partnership 2018-19 University of Strathclyde | Obiora, Chukwuebuka Richard
Rattray, Zahra (Principal Investigator) Drummond, Robert (Co-investigator) Obiora, Chukwuebuka Richard (Research Co-investigator)
01-Jan-2019 - 01-Jan-2023
Nanomedicine-protein interactions: Understanding protein corona composition effects on nanomedicine cellular uptake
Rattray, Zahra (Principal Investigator) Seib, Philipp (Academic)
From bench to clinic, a new drug candidate will face multiple roadblocks and challenges in its development. In oncology drug development, a balance has to be met between achieving tumour bioavailability and potential off-target organ toxicity- Nanomedicines have emerged as a promising solution to overcoming such challenges.
When administered intravenously, a nanomedicine will be exposed to various biomolecules in blood. Some of these molecules will adsorb onto the nanomedicine surface, forming a ‘corona’, altering its chemical identity and biological fate. Corona composition is unique to nanomedicine type and characteristics, and has been linked to the success of tumour drug delivery.
We are looking for applicants to join our exciting project that will seek to understand nanomedicine characteristics that are key to impacting the biological fate of nanoparticles using a systematic approach. The successful candidate will apply cutting-edge technologies for characterizing nanomedicine characteristics, study protein corona composition in biological media, impact on subsequent cellular uptake, and develop novel biochemical assays that will aid the prediction of nanomedicine biological fate. This PhD project will be highly-suited to candidates from a pharmaceutical sciences, chemistry, or engineering background who are keen to develop skills in analytical chemistry, molecular biology and cell culture.
01-Jan-2019 - 01-Jan-2023
Silencing KPNA2: A Druggable Target for Breast Cancer?
Rattray, Zahra (Principal Investigator)
01-Jan-2019 - 31-Jan-2020
Silencing KPNA2: A Druggable Target Against Breast Cancer?
Rattray, Zahra (Principal Investigator)
01-Jan-2019 - 31-Jan-2020

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Robertson Wing

Location Map

View University of Strathclyde in a larger map